Xin Lang Cai Jing·2026-02-27 05:49Core Viewpoint - The article discusses the ongoing legal actions against Ningke Biological (600165) for false statements and the implications for investors seeking compensation due to the company's financial misconduct [1][7]. Group 1: Ningke Biological's Legal Issues - Ningke Biological is facing a lawsuit for false statements, with a recent case submitted to the court by attorney Xu Feng [1][7]. - The company inflated its 2022 revenue by 76.59 million yuan and profit by 77.22 million yuan, representing 11.25% and 46.59% of its total revenue and profit, respectively [1][7]. - The company failed to timely disclose significant events, including major debts, frozen bank accounts, and the suspension of its subsidiary's main business [2][3][4]. Group 2: Investor Compensation Opportunities - Investors who purchased Ningke Biological shares between November 22, 2022, and April 6, 2023, or between April 28, 2023, and October 31, 2024, may initiate claims for compensation [5][9]. - The law firm is also handling claims for investors of Shandong Zhanggu (002598), which is under investigation for financial disclosure violations [5][10]. - Investors who bought Shandong Zhanggu shares before January 1, 2026, and sold or held them afterward are eligible to file for compensation [6][10].